Should I start mirtazapine at 7.5 mg nightly for only three nights before lowering to 3.75 mg, and how long should the initial dose be continued?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Mirtazapine Dosing: Start at 7.5 mg and Stay There

Starting mirtazapine at 7.5 mg for only three nights before dropping to 3.75 mg is not supported by evidence and contradicts FDA-approved dosing. The FDA-approved starting dose is 15 mg nightly, with dose changes made no more frequently than every 1-2 weeks 1. However, for specific indications like insomnia or when sedation is desired, 7.5 mg nightly is an appropriate and evidence-based starting dose that should be maintained, not reduced further 2, 3.

The Evidence-Based Approach

Standard Dosing (Depression)

  • FDA-approved starting dose: 15 mg nightly 1
  • Titrate up to maximum 45 mg daily based on response
  • Dose changes should occur no more frequently than every 1-2 weeks to allow adequate time to assess response 1

Lower-Dose Strategy (Insomnia/Sedation)

Multiple clinical practice guidelines consistently recommend 7.5 mg as the starting dose when mirtazapine is used for insomnia or when sedative effects are prioritized 2, 3:

  • 7.5 mg at bedtime is the established low-dose regimen 2
  • Can titrate up to 30 mg for insomnia if needed 3
  • This dose "promotes sleep, appetite, and weight gain" 2
  • Particularly effective in patients with comorbid depression and anorexia 3

Why 3.75 mg Makes No Sense

There is no clinical evidence supporting 3.75 mg dosing:

  • Research on "ultra-low-dose" mirtazapine (3.75 mg) shows only preliminary retrospective data 4
  • The 7.5 mg dose has been studied in controlled trials and shows efficacy for insomnia 5
  • Dropping from 7.5 mg to 3.75 mg after only 3 nights doesn't allow time to assess response and contradicts the FDA guidance requiring 1-2 weeks between dose changes 1

Clinical Algorithm

If treating depression:

  1. Start 15 mg nightly 1
  2. Wait 1-2 weeks minimum before adjusting
  3. Increase by 15 mg increments up to 45 mg maximum based on response

If treating insomnia (with or without depression):

  1. Start 7.5 mg at bedtime 2, 3
  2. Maintain this dose for at least 1-2 weeks 1
  3. If inadequate response, increase to 15 mg, then 30 mg as needed
  4. Do not reduce below 7.5 mg—there's no evidence base for lower dosing

If treating anxiety/agitation in palliative care:

  1. Start 7.5-30 mg at bedtime 3
  2. Adjust based on symptom control and tolerability

Critical Pitfalls to Avoid

  • Don't make dose changes more frequently than every 1-2 weeks 1—you won't have adequate time to assess therapeutic response
  • Don't reduce to 3.75 mg—this dose lacks evidence and may be subtherapeutic
  • Don't confuse mirtazapine's paradoxical dose-response: Lower doses (7.5-15 mg) are MORE sedating due to predominant H1 antihistamine effects, while higher doses (30-45 mg) have more noradrenergic activity and may be less sedating 2
  • Monitor for next-day sedation and cognitive impairment, especially in elderly patients 5
  • Watch for weight gain and increased appetite, which occur at all doses 2, 5

The Bottom Line

If you started at 7.5 mg, stay at 7.5 mg for at least 1-2 weeks before making any changes. Dropping to 3.75 mg after 3 nights has no evidence base and violates basic pharmacologic principles of allowing adequate time for therapeutic assessment. The 7.5 mg dose is well-established in clinical guidelines for insomnia and sedation 2, 3, while 3.75 mg exists only in preliminary retrospective data 4.

References

Guideline

palliative care version 1.2016.

Journal of the National Comprehensive Cancer Network : JNCCN, 2016

Research

Efficacy and Tolerability of Ultra-Low-Dose Mirtazapine in Adult Chronic Insomnia.

The primary care companion for CNS disorders, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.